V. Sridhar

发表

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?

D. Cherney, Vikas S Sridhar, H. U. Rahman, 2020, Diabetes, obesity & metabolism.

Role of endogenous adenine in kidney failure and mortality with diabetes

B. Kestenbaum, I. D. de Boer, S. Waikar, 2023, medRxiv.

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

J. Rosenstock, B. Perkins, Hongyan Liu, 2022, Current Diabetes Reports.

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.

P. Lawler, D. Cherney, J. Boulet, 2021, Metabolism: clinical and experimental.

Sex and Gender Related Differences in Diabetic Kidney Disease.

J. Benham, D. Campbell, D. Cherney, 2022, Seminars in nephrology.

Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials

C. Mathieu, P. Gillard, Y. Lytvyn, 2021, Transplantation.

Sex and Gender Considerations in Transplant Research: A Scoping Review.

Katherine M. Cole, L. Pilote, R. Sapir-Pichhadze, 2019, Transplantation.

Cardiorenal Protection in Diabetic Kidney Disease

D. Cherney, A. Odutayo, Vikas S Sridhar, 2021, Endocrinology and metabolism.

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection

Lisa Dubrofsky, D. Cherney, J. Boulet, 2020, Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia.

Sex and gender considerations in transplantation research: protocol for a scoping review

L. Pilote, R. Sapir-Pichhadze, L. West, 2017, Systematic Reviews.

Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes

P. Lawler, L. E. Lovblom, B. Perkins, 2021, Diabetes, obesity & metabolism.

Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease

D. Cherney, Vikas S Sridhar, Mohanad Almaimani, 2021, Current opinion in nephrology and hypertension.

SGLT2 Inhibitors: The Sweet Success for Kidneys.

D. Cherney, Atit Dharia, Vikas S. Sridhar, 2023, Annual review of medicine.

Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon

M. Kanbay, A. Kanbay, D. Cherney, 2022, Sleep and Breathing.

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes

P. Lawler, D. Burger, K. Burns, 2021, Kidney international reports.

Premature Death in Kidney Transplant Recipients: The Time for Trials is Now.

B. Kasiske, S. Chadban, V. Jha, 2022, Journal of the American Society of Nephrology : JASN.

Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting.

N. Seymour, Vikas S Sridhar, Philemon Leung, 2014, Canadian family physician Medecin de famille canadien.

Associations Among Biomarkers of Inflammation, Tubular Injury and Lipid Metabolism With Gestational Diabetes Mellitus Status, Microalbuminuria and Retinopathy in the Microalbuminuria and Retinopathy in Gestational Diabetes Study.

D. Feig, B. Shah, L. E. Lovblom, 2022, Canadian journal of diabetes.

Case - Reflex anuria: A rare complication of retrograde pyelography.

D. Cherney, N. Perlis, Atit Dharia, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

SGLT2 inhibition, glucose transport and peritoneal dialysis: Finding the sweet spot

D. Fraser, V. Sridhar, 2023, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients

B. Kestenbaum, I. D. de Boer, L. Natarajan, 2023, The Journal of clinical investigation.

Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease.

L. E. Lovblom, B. Perkins, J. Lovshin, 2021, Journal of diabetes and its complications.

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.

P. Groop, H. Heerspink, Christine P. Limonte, 2023, Diabetologia.

Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes.

Y. Lytvyn, D. Cherney, V. Sridhar, 2024, Diabetes research and clinical practice.

Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD

A. Odutayo, V. Sridhar, Deepak L. Bhatt, 2024, Clinical journal of the American Society of Nephrology : CJASN.